Linezolid vs Vancomycin/Cefazolin in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linezolid (Primary) ; Cefazolin; Gentamicin; Vancomycin
Indications Bacteraemia; Catheter infections; Gram-positive infections
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

31 Jul 2022 This trial has been completed in Slovakia (End Date: 18 Sep 2006), according to European Clinical Trials Database record.
11 Apr 2022 This trial has been completed in Spain (End Date: 18 Sep 2006), according to European Clinical Trials Database record.
28 Sep 2008 Planned end date (Sep 2006) added as reported by CT.gov

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight